Analysis the Effectiveness of Remdesivir, Galidesivir, Sofosbuvir, Tenofovir and Ribavirin as Potential Therapeutic Drug target against SARS-Cov-2 RNA-Dependent RNA Polymerase (RdRp): An in Silico Docking Study

Analysis the Effectiveness of Remdesivir, Galidesivir, Sofosbuvir, Tenofovir and Ribavirin as Potential Therapeutic Drug target against SARS-Cov-2 RNA-Dependent RNA Polymerase (RdRp): An in Silico Docking Study

Background & Aims: The active site of RdRp-CoV is highly conserved, with two successive and surface-accessible aspartates in a beta-turn structure. Antiviral drugs Remdesivir, Galidesivir, Tenofovir, Sofosbuvir, and Ribavirin are known as inhibitors of RdRps, while lopinavir and rotinavir are k...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Rajneesh Prajapat, Suman Jain
Format:	Artikel
Sprache:	English
Veröffentlicht:	Urmia University of Medical Sciences 2023-07-01
Schriftenreihe:	Journal of Research in Applied and Basic Medical Sciences
Schlagworte:	antiviral drugs fda in silico remdesivir rdrp sars-cov-2
Online Zugang:	http://ijrabms.umsu.ac.ir/article-1-261-en.pdf

Ähnliche Einträge

SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
von: Jung Sun Min, et al.
Veröffentlicht: (2021-08-01)

In silico study of the flavonoid compound of Sauropus androgynus leaves ON RNA-Dependent RNA polymerase (RdRp) SARS-CoV-2
von: Aghnia Nabila Ananda, et al.
Veröffentlicht: (2024-06-01)

Influence of SARS-CoV-2 variants’ spike glycoprotein and RNA-dependent RNA polymerase (nsp12) mutations on remdesivir docking residues
von: Ali A. Dawood
Veröffentlicht: (2022-07-01)

Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp)
von: Anandakrishnan Karthic, et al.
Veröffentlicht: (2022-01-01)

Triple targeting of human IMPDH, SARS-CoV-2 RdRp, and Rhizopus oryzae RdRp: An in silico perspective
von: Abdel-moniem S. Hassan, et al.
Veröffentlicht: (2023-12-01)

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
von: Francesca Picarazzi, et al.
Veröffentlicht: (2020-12-01)

Identification of a New Drug Binding Site in the RNA-Dependent-RNA-Polymerase (RdRp) Domain
von: Aparna S. Gana, et al.
Veröffentlicht: (2023-10-01)

Limited Short-Term Evolution of SARS-CoV-2 RNA-Dependent RNA Polymerase under Remdesivir Exposure in Upper Respiratory Compartments
von: Vladimir Novitsky, et al.
Veröffentlicht: (2024-09-01)

Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp
von: Zhuang Wang, et al.
Veröffentlicht: (2022-06-01)

Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay
von: Timsy Uppal, et al.
Veröffentlicht: (2022-08-01)

Covalent Inhibitors from Saudi Medicinal Plants Target RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2
von: Ahmed H. Bakheit, et al.
Veröffentlicht: (2023-10-01)

In silico screening of drug inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase target
von: Thanh Tung Bui, et al.
Veröffentlicht: (2022-03-01)

Monoclonal antibody against EV71 3Dpol inhibits the polymerase activity of RdRp and virus replication
von: Yaoming Li, et al.
Veröffentlicht: (2019-01-01)

RdRp mutations are associated with SARS-CoV-2 genome evolution
von: Doğa Eskier, et al.
Veröffentlicht: (2020-07-01)

Discovery of SARS-CoV-2 RNA-dependent-RNA-polymerase (RdRp) Inhibitor from Sambiloto (Andrographis paniculata) Based on Molecular Docking and ADMET Prediction Approach
von: Dina Ahsana, et al.
Veröffentlicht: (2022-08-01)

Design, Synthesis, Evaluation and Molecular Dynamics Simulation of Dengue Virus NS5-RdRp Inhibitors
von: Keli Zong, et al.
Veröffentlicht: (2023-11-01)

The RdRp genotyping of SARS-CoV-2 isolated from patients with different clinical spectrum of COVID-19
von: Michał Majchrzak, et al.
Veröffentlicht: (2024-03-01)

Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors
von: Shenghua Gao, et al.
Veröffentlicht: (2022-12-01)

Remdesivir inhibits Porcine epidemic diarrhea virus infection in vitro
von: Zi-Xin Huang, et al.
Veröffentlicht: (2023-11-01)

Diterpenoids target SARS-CoV-2 RdRp from the roots of Euphorbia fischeriana Steud
von: Ting Ruan, et al.
Veröffentlicht: (2024-07-01)

Uncovering Gender and Age Neutrality in CT Values for E and RdRp Gene Amplification in SARS-CoV-2
von: Ibrahim A. Naqid, et al.
Veröffentlicht: (2023-12-01)

Study of Eclipta prostrata compounds with potential inhibition of RNA-dependent RNA polymerase (RdRp) enzyme of Sars-CoV-2 virus using molecular docking
von: Hồ Thiên Hoàng, et al.
Veröffentlicht: (2023-08-01)

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
von: Mekonnen Sisay
Veröffentlicht: (2020-05-01)

Interaction of Sesbania mosaic virus (SeMV) RNA-dependent RNA polymerase (RdRp) with the p10 domain of polyprotein 2a and its implications in SeMV replication
von: Kunduri Govind, et al.
Veröffentlicht: (2014-01-01)

An Efficient Modern Strategy to Screen Drug Candidates Targeting RdRp of SARS-CoV-2 With Potentially High Selectivity and Specificity
von: Haiping Zhang, et al.
Veröffentlicht: (2022-07-01)

Molecular Evolutionary Analyses of the RNA-Dependent RNA Polymerase (<i>RdRp</i>) Region and <i>VP1</i> Gene in Sapovirus GI.1 and GI.2
von: Fuminori Mizukoshi, et al.
Veröffentlicht: (2025-02-01)

SMILES-based QSAR virtual screening to identify potential therapeutics for COVID-19 by targeting 3CLpro and RdRp viral proteins
von: Faezeh Bazzi-Allahri, et al.
Veröffentlicht: (2024-10-01)

Efficient elimination of RNA mycoviruses in aspergillus species using RdRp-inhibitors ribavirin and 2’-C-methylribonucleoside derivatives
von: Ayano Ikeda, et al.
Veröffentlicht: (2022-10-01)

Molecular modelling and simulation techniques to investigate the effects of fungal metabolites on the SARS-CoV-2 RdRp protein inhibition
von: Uday M. Muddapur, et al.
Veröffentlicht: (2022-08-01)

Nucleotide Analogues Bearing a C2′ or C3′-Stereogenic All-Carbon Quaternary Center as SARS-CoV-2 RdRp Inhibitors
von: Amarender Manchoju, et al.
Veröffentlicht: (2022-01-01)

Mutation density changes in SARS-CoV-2 are related to the pandemic stage but to a lesser extent in the dominant strain with mutations in spike and RdRp
von: Doğa Eskier, et al.
Veröffentlicht: (2020-08-01)

Virtual screening based on the structure of more than 105 compounds against four key proteins of SARS-CoV-2: MPro, SRBD, RdRp, and PLpro
von: Farzan Nabati, et al.
Veröffentlicht: (2022-01-01)

Natural Products from Red Algal Genus <i>Laurencia</i> as Potential Inhibitors of RdRp and nsp15 Enzymes of SARS-CoV-2: An In Silico Perspective
von: Omkar Pokharkar, et al.
Veröffentlicht: (2023-07-01)

A Novel MicroRNA From the Translated Region of the Giardiavirus rdrp Gene Governs Virus Copy Number in Giardia duodenalis
von: Pengtao Gong, et al.
Veröffentlicht: (2020-11-01)

Molecular Evolutionary Analyses of the RNA-Dependent RNA Polymerase (<i>RdRp</i>) Region and <i>VP1</i> Gene in Human Norovirus Genotypes GII.P6-GII.6 and GII.P7-GII.6
von: Tomoko Takahashi, et al.
Veröffentlicht: (2023-07-01)

Derivation, Functionalization of (S)-Goniothalamin from <i>Goniothalamus wightii</i> and Their Derivative Targets SARS-CoV-2 M<sup>Pro</sup>, S<sup>Pro</sup>, and RdRp: A Pharmacological Perspective
von: Vino Palani, et al.
Veröffentlicht: (2022-10-01)

Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp)
von: Yifei Wu, et al.
Veröffentlicht: (2021-12-01)

Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases
von: Federica Riccio, et al.
Veröffentlicht: (2019-01-01)

Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses
von: Chiranjib Chakraborty, et al.
Veröffentlicht: (2023-07-01)

Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
von: Jiangtao Bai, et al.
Veröffentlicht: (2025-01-01)